Jan 27 2018
Eagle Biosciences, Inc. is proud to announce the launch of a new assay, MedFrontier FGF23 (Human Intact FGF23) ELISA Assay Kit. This assay was developed and manufactured by Kyowa Medex Co., Ltd from Tokyo, Japan. Much like Eagle Biosciences, Kyowa Medex specializes in in vitro diagnostics and medical devices. They have been dedicated to being a company focused on R&D and substantiated by creative and evolutional research and technology.
“We are very honored to be working with the team at Kyowa Medex,” said Dan Keefe, President of Eagle Biosciences. “Introducing the Intact FGF23 Assay with such a broad dynamic range while maintaining an easier assay procedure is really changing the game in FGF23 research.”
MedFrontier FGF23 (Human Intact FGF23) ELISA Assay Kit utilizes a simple 96 well sandwich ELISA procedure that measures only the full-length active form (intact form) in under three hours. FGF23 is being researched in the context of X-linked hypophosphatemic rickets, mineral bone disorder (MBD), chronic kidney disease (CKD), tumor-induced osteomalacia and hyperphosphatemia.
The Intact FGF23 ELISA Assay Kit from Eagle Biosciences is currently for research use only.
Monash-led study unveils potential long-term treatment for lupus